Top Markets
#1 ONFA ONFA +217.91%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +36.64%
#6 NKN NKN +34.87%
#7 StakeStone StakeStone +29.44%
#8 BLOCKv BLOCKv +25.50%
#9 KONET KONET +24.76%
#10 OpenVPP OpenVPP +21.34%
Coin of the day
ONFA ONFA
設定
言語
日本
通貨
USD
テーマ
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
株式のランク #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
株価
$0.5275
時価総額
$1.25M
変化（1日）
-3.56%
変化（1年）
-83.77%
国
US
取引 Ensysce Biosciences, Inc. (ENSC)

カテゴリー

Healthcare
Ensysce Biosciences, Inc.（ENSC）の営業利益率
March 2026 時点の営業利益率 TTM: -245.89%
Ensysce Biosciences, Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は -245.89% です。2023 年末時点では -480.41% でした。
Ensysce Biosciences, Inc. の営業利益率の履歴（2017 から 2026）
各年末の営業利益率
年 営業利益率 変化
2026 (TTM) -245.89% 90.36%
2024 -129.17% -73.11%
2023 -480.41% -49.96%
2022 -960.05% 70.61%
2021 -562.73% 1,271.51%
2020 -41.03% -78.26%
2019 -188.72% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
41.30% -100.17%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
35.45% -100.14%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
24.95% -100.10%
US
UCB SA UCB SA
UCB SA
UCB.BR
25.32% -100.10%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.10%
AU
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。